Because covid-19 detected Andon Health Co.Ltd(002432) (002432, SZ; yesterday’s closing price of 56.91 yuan) and stepped on the “letter Phi” pit.
On February 14, Andon Health Co.Ltd(002432) announced that the company had recently received the decision on administrative regulatory measures (hereinafter referred to as the decision) and the decision on taking regulatory talk measures against Liu Yi and Wu Tong from Tianjin Securities Regulatory Bureau.
According to the decision, Andon Health Co.Ltd(002432) did not show the results of “60% detection” and “completely undetectable” in the samples of the experimental group when it first disclosed the performance test report of ihealth covid-19 antigen home self-test OTC kit against Omicron mutant virus, which was considered to be incomplete.
In this regard, Andon Health Co.Ltd(002432) Secretary of the board of directors told the reporter of the daily economic news that “(the situation) is described in the announcement and does not need to be broken down”. However, insiders told reporters that the company hid some experimental information of covid-19 detection kit, that is, “when the sample concentration is low, it is completely unable to detect”.
The picture is drawn by Liu Hongmei according to the official website of Andon Health Co.Ltd(002432)
penalty for incomplete product information
According to the decision, on January 7, Andon Health Co.Ltd(002432) disclosed the performance test report of the ihealth covid-19 antigen home self-test OTC kit against Omicron mutant virus, saying that “the ihealth covid-19 antigen rapid test detected 100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5)”.
However, on January 15, Andon Health Co.Ltd(002432) replied to the attention letter of Shenzhen Stock Exchange, saying that in the report previously disclosed by the company, “maximum” means that samples less than or equal to 21.59 can be 100% detected, and samples greater than 21.59 cannot be 100% detected, It also said that “the positive detection rate of all samples in the experimental group: when the CT value is ≤ 21.59, it can be detected completely, when the CT value is 22.86, it can be detected 60%, and when the CT value is ≥ 23.87, it can not be detected at all.”
According to the decision, Andon Health Co.Ltd(002432) only disclosed some successful test results on January 7, 2022, but did not disclose all the test results, and the disclosure information was incomplete. Liu Yi, chairman and general manager of the company, and Wu Tong, Secretary of the board of directors, failed to perform their duties faithfully and diligently during their tenure, violating Article 4 of the measures for the administration of information disclosure of listed companies.
According to the provisions of articles 51 and 52 of the measures for the administration of information disclosure of listed companies, it is decided to take the supervision and administration measures for the two people’s regulatory conversation, and require them to bring valid identity documents to Tianjin Securities Regulatory Bureau for regulatory conversation before February 18 (this Friday).
On this matter, the reporter of the daily economic news contacted the Secretary of Andon Health Co.Ltd(002432) on February 14, and the other party said that “it is the announcement on the experimental situation disclosed in the early stage. The supervisor believes that the integrity is not good, so he wants to talk to us and guide the work” and “there is no need to over interpret”.
the industry believes that the data are misleading
Although in the announcement on January 5, Andon Health Co.Ltd(002432) stated that “early data show that the antigen detection kit can detect Omicron variant virus, but its sensitivity may be reduced”, it did not clarify the conditions and details of the reduction of product sensitivity in combination with the experimental data.
According to the announcement issued on Andon Health Co.Ltd(002432) January 15, in the above experiment, the lower the CT value, the smaller the number of cycles experienced when representing the set domain value, and the higher the concentration of the sample to be tested. In reverse analysis, the greater the CT value, the lower the concentration of the sample to be tested.
Based on this, the reporter contacted an industry insider about the difference and meaning of the data disclosed twice. The other party believed that the data given by Andon Health Co.Ltd(002432) for the first time was misleading.
Specifically, when “CT value ≤ 21.59, all products can be detected”, the sample concentration is the highest, and all products can be detected. The sample concentration of “CT value 22.86” is medium, and the product detection rate is 60%. The sample concentration of “CT value ≥ 23.87” is the lowest, and the product detection rate is 0.
The source told reporters that Andon Health Co.Ltd(002432) the first disclosure of data is easy to give investors an impression, which can make people form the impression that in the test performance experiment, the concentration of the test samples is relatively high, and all are detected by the products, and the detection rate of the products is unknown when the concentration is reduced.
According to the performance data of {432-0022} in the third test, the performance of the company’s medium and low co19-0022} test kits can not be supplemented according to the performance data of the third test.
The industry added that “the CT value is 23.87, but the concentration is not very low”.
The reporter asked another person in the industry for confirmation on the above contents. The other party recognized the above views and added that the important indicators for evaluating antigen reagents are sensitivity and specificity, but Andon Health Co.Ltd(002432) has not published all these data at present.
